186 related articles for article (PubMed ID: 27137418)
1. Evolving treatments for advanced gastric cancer: appraisal of the survival trend.
Roberto M; Romiti A; Onesti CE; Zullo A; Falcone R; Marchetti P
Expert Rev Anticancer Ther; 2016 Jul; 16(7):717-29. PubMed ID: 27137418
[TBL] [Abstract][Full Text] [Related]
2. Targeted Treatment of Esophagogastric Cancer.
Kopp HG; Hofheinz RD
Oncol Res Treat; 2016; 39(12):788-794. PubMed ID: 27889780
[TBL] [Abstract][Full Text] [Related]
3. Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer.
Noronha V; Patil VM; Joshi A; Chougule A; Banavali S; Prabhash K
Cancer Lett; 2017 Aug; 400():267-275. PubMed ID: 28109908
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
5. Predictive biomarkers along gastric cancer pathogenetic pathways.
Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
[TBL] [Abstract][Full Text] [Related]
6. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
[TBL] [Abstract][Full Text] [Related]
7. Optimal management of gastroesophageal junction cancer.
Greally M; Agarwal R; Ilson DH
Cancer; 2019 Jun; 125(12):1990-2001. PubMed ID: 30973648
[TBL] [Abstract][Full Text] [Related]
8. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.
Onesti CE; Romiti A; Roberto M; Falcone R; Marchetti P
Expert Rev Anticancer Ther; 2015; 15(10):1183-98. PubMed ID: 26325474
[TBL] [Abstract][Full Text] [Related]
9. Emerging mAbs for the treatment of esophagogastric cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
[TBL] [Abstract][Full Text] [Related]
10. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Briasoulis E; Fatouros M; Roukos DH
Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
[No Abstract] [Full Text] [Related]
11. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
12. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
13. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers and novel agents in esophago-gastric cancer: are we making progress?
Dahle-Smith A; Petty RD
Expert Rev Anticancer Ther; 2015; 15(9):1103-19. PubMed ID: 26313419
[TBL] [Abstract][Full Text] [Related]
15. Perspectives of HER2-targeting in gastric and esophageal cancer.
Gerson JN; Skariah S; Denlinger CS; Astsaturov I
Expert Opin Investig Drugs; 2017 May; 26(5):531-540. PubMed ID: 28387541
[TBL] [Abstract][Full Text] [Related]
16. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
20. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
Roberto M; Romiti A; Onesti CE; D'Antonio C; Milano A; Falcone R; Barucca V; Palombi L; Righini R; Marchetti P
Anticancer Drugs; 2016 Feb; 27(2):106-11. PubMed ID: 26473528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
